“PierianDx is a leader in enabling precision medicine and I am confident that this partnership will significantly accelerate our shared vision of bringing genomics and personalized medicine into everyday healthcare.”
Tute Genomics was founded in 2012 and during that timespan, they’ve done a lot of cool things. First and foremost, they’ve embarked on a mission to personalize medicine through genome analysis, which is awesome and hopefully happens sooner rather than later. They have been accepted into multiple Utah-based accelerators — BoomStartup and Healthbox — and parlayed that experience into multiple funding rounds, including a $3.9 million Series A1 round in June 2015. They shared large amounts of genetic information with Google Genomics, then acquired Knome to boost their support system for genome interpretation.
All of these actions have led us to today. St. Louis-based PierianDx, also a company greatly invested in bringing personalized medicine to the masses, has acquired Tute Genomics.
“PierianDx is a leader in enabling precision medicine and I am confident that this partnership will significantly accelerate our shared vision of bringing genomics and personalized medicine into everyday healthcare,” Reid Robison, CEO of Tute, said in a statement.
As part of the transaction, a few things will happen. The most obvious: both platforms will begin to combine, with spring of 2017 the hopeful timeframe for full integration. Robison will join the PierianDx Board of Directors, while PierianDx will continue to maintain a development team in Provo. Last but not least, two Tute higher-ups — COO Andy Olson and VP of Product Development Bryce Daines — will relocate to St. Louis and presumably celebrate like prominent St. Louis citizens are known to do.
